{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:08:16Z","timestamp":1793725696830,"version":"4.6.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To date, no post-marketing safety studies of satralizumab have been conducted. This study aims to evaluate the post-marketing safety profile of satralizumab using data from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) databases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We extracted all adverse event (AE) reports related to satralizumab from the FAERS database covering the period from Q1\u20132023 to Q4 2024. Disproportionality analyses were conducted for AEs with at least four reports listing satralizumab as the primary suspect (PS), using Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS), along with their corresponding 95% confidence intervals (CI). Non-parametric tests were applied to compare differences between serious and non-serious outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Since its approval, a total of 2,527 AEs related to satralizumab have been reported in the FAERS database, involving 931 individual patients. Among them, 355 patients experienced serious outcomes, including 389 fatal cases. The most frequently reported AEs were infection-related, such as urinary tract infection (n = 72), infectious pneumonia (n = 44), COVID-19 (n = 43), sepsis (n = 23), and cellulitis (n = 17). In addition, several unexpected AEs were identified, including cerebral infarction and malignancies. Compared with patients experiencing non-serious outcomes, male patients were more likely to develop serious outcomes, which also tended to occur earlier in the treatment course. Furthermore, the standard usage (120 mg once every 2 weeks for three doses at Weeks 0, 2, and 4, followed by 120 mg once every 4 weeks) was associated with a relatively favorable safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The adverse risks associated with satralizumab are notable. Our findings provide evidence to support risk assessment in clinical practice; however, high-quality clinical studies are still needed to validate these results and to further explore the long-term safety and efficacy of the drug.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1647306","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T05:15:47Z","timestamp":1768367747000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Disproportionality analysis of satralizumab in FDA adverse event reporting system and Japanese adverse drug event report: a pharmacovigilance study"],"prefix":"10.3389","volume":"16","author":[{"given":"Linhai","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Zunyi Medical University","place":["Guizhou, China"]},{"name":"Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Zunyi Medical University","place":["Guizhou, China"]},{"name":"Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zucai","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Zunyi Medical University","place":["Guizhou, China"]},{"name":"Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-00995-9","article-title":"Satralizumab: A review in neuromyelitis optica spectrum disorder","volume":"37","author":"Fung","year":"2025","journal-title":"CNS Drugs"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104025","article-title":"Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar","volume":"66","author":"Yamamura","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510059","article-title":"Pragmatic trials","volume":"375","author":"Ford","year":"2016","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2008.12.012","article-title":"Decision support methods for the detection of adverse events in post-marketing data","volume":"14","author":"Hauben","year":"2023","journal-title":"Drug Discov Today"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4944","article-title":"Quality evaluation of the Japanese Adverse Drug Event Report database (JADER)","volume":"29","author":"Tsuchiya","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12916-025-04031-z","article-title":"Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data","volume":"23","author":"Massy","year":"2025","journal-title":"BMC Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/life10080138","article-title":"Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance","volume":"10","author":"Park","year":"2009","journal-title":"Life (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/amiajnl-2012-001119","article-title":"Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records","volume":"20","author":"Liu","year":"2020","journal-title":"J Am Med Inform Assoc"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/2047487320915663","article-title":"Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system","volume":"28","author":"Gatti","year":"2014","journal-title":"Eur J Prev Cardiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2023","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2025","journal-title":"J Neuroinflamm"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3109\/00207454.2016.1163550","article-title":"Th17 cells in neuromyelitis optica spectrum disorder: a review","volume":"126","author":"Lin","year":"2016","journal-title":"Int J Neurosci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103826","article-title":"Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab","volume":"24","author":"Li","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2025","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optic a spectrum disorder: a randomized, double-blind, multicenter, placebo- controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1322412","article-title":"Neuromyelitis optica spectrum disorder safely and successfully treated with satralizumab during pregnancy and breastfeeding: a case report","volume":"14","author":"Yoshida","year":"2023","journal-title":"Front Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1257955","article-title":"Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report","volume":"14","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs ap proved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2020","journal-title":"Drug Saf"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106444","article-title":"Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and U S-based health claims data","volume":"99","author":"Greenberg","year":"2015","journal-title":"Mult Scler Relat Disord"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200124","article-title":"International Delphi consensus on the management of AQP4-igG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab","volume":"10","author":"Paul","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01380-2","article-title":"Satralizumab: first approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578585","article-title":"Satralizumab treatment in patients with AQP4-IgG-seropositive neuromye litis optica spectrum disorder after rituximab treatment: A case series","volume":"403","author":"Abboud","year":"2023","journal-title":"J Neuroimmunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1647306\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T05:15:48Z","timestamp":1768367748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1647306\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2025.1647306"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1647306","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1647306"}}